Developing
breakthrough treatment for 
dyskinesia
PolyCore is committed to applying novel science to give patients with Parkinson’s Disease and other CNS disorders better quality of life.

Our lead compound, PCT-3012, targets dyskinesia and cognitive impairment associated with neurodegenerative disorders and is currently in preclinical studies for treatment of motor symptoms and dyskinesia in patients with early- to mid-stage Parkinson’s Disease (PD).

Advancing PCT-3012

for Levodopa-Induced Dyskinesia​

PolyCore’s PCT-3012 novel dopamine D3 receptor agonist is designed to modify how L-dopa works instead of negating its effects, to improve motor symptoms without the development of tolerance, dyskinesia or impulsive behaviors.

Did You Know?

Levodopa (L-dopa), discovered in the late 1960s, is still the gold standard gold standard for treating PD symptoms today.

 

After 4-10 years of treatment, ~50% of patients experience “L-dopa induced dyskinesia” (LID).

 

LID manifests as abnormal involuntary body movements that can interfere with daily life.

The Latest from PolyCore

A Promising Pipeline

How can PCT-3012’s differentiated mechanism of action address other CNS disorders?